We are live on ! Find out more
SGAM

Smith Group Asset Management Portfolio holdings

AUM $2.46B
1-Year Est. Return 57.16%
This Fund
S&P 500
This Quarter Est. Return
+31.89%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
-$18.2M
Cap. Flow
-$444M
Cap. Flow %
-24.46%
Top 10 Hldgs %
40.04%
Holding
396
New
38
Increased
53
Reduced
183
Closed
98

Top Buys

Rank Stock Value
1
HOLX
Hologic
HOLX
+$24.1M
2
PH icon
Parker-Hannifin
PH
+$20.9M
3
AMP icon
Ameriprise Financial
AMP
+$15.8M
4
THS
Treehouse Foods
THS
+$12.2M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.1M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$48.5M
2
MSFT icon
Microsoft
MSFT
+$45.5M
3
BIIB icon
Biogen
BIIB
+$36M
4
AMZN icon
Amazon
AMZN
+$29.7M
5
BURL icon
Burlington
BURL
+$25.3M

Sector Composition

Rank Sector Weight
1 Technology 38.49%
2 Healthcare 16.85%
3 Consumer Discretionary 12.94%
4 Communication Services 8.43%
5 Industrials 7.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFBC icon
176
Preferred Bank
PFBC
$1.25B
$151K 0.01%
3,520
-50
-1% -$1.84K
BPMC
177
DELISTED
Blueprint Medicines
BPMC
$145K 0.01%
1,860
-30
-2% -$2.03K
FBM
178
DELISTED
Foundation Building Materials, Inc. Common Stock
FBM
$145K 0.01%
9,300
-140
-1% -$1.77K
ARWR icon
179
Arrowhead Research
ARWR
$12.5B
$143K 0.01%
3,310
-50
-1% -$1.76K
FCN icon
180
FTI Consulting
FCN
$4.17B
$142K 0.01%
1,240
-30
-2% -$3.63K
HALO icon
181
Halozyme
HALO
$12.2B
$142K 0.01%
5,290
-60
-1% -$1.35K
EBS icon
182
Emergent Biosolutions
EBS
$229M
$139K 0.01%
1,760
-30
-2% -$2.24K
XLRN
183
DELISTED
Acceleron Pharma
XLRN
$129K 0.01%
1,350
-20
-1% -$1.93K
SEM
184
DELISTED
Select Medical
SEM
$127K 0.01%
15,962
-148
-0.9% -$1.23K
GBT
185
DELISTED
Global Blood Therapeutics, Inc.
GBT
$124K 0.01%
1,970
-30
-2% -$2.06K
FOLD
186
DELISTED
Amicus Therapeutics
FOLD
$123K 0.01%
8,180
-100
-1% -$1.22K
CVI icon
187
CVR Energy
CVI
$3.26B
$117K 0.01%
5,834
-70
-1% -$1.41K
IOVA icon
188
Iovance Biotherapeutics
IOVA
$2.9B
$114K 0.01%
4,150
-40
-1% -$1.31K
PTCT icon
189
PTC Therapeutics
PTCT
$6.23B
$110K 0.01%
2,170
-30
-1% -$1.47K
SANM icon
190
Sanmina
SANM
$10.7B
$109K 0.01%
4,350
-50
-1% -$1.32K
NTRA icon
191
Natera
NTRA
$45.9B
$108K 0.01%
2,170
-30
-1% -$1.2K
MRTX
192
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$106K 0.01%
930
-20
-2% -$1.94K
BRK.B icon
193
Berkshire Hathaway Class B
BRK.B
$1.14T
$105K 0.01%
589
-3
-0.5% -$548
NVTA
194
DELISTED
Invitae Corporation
NVTA
$104K 0.01%
3,420
-40
-1% -$698
MNTA
195
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$104K 0.01%
3,120
-30
-1% -$955
KYNB
196
Kyntra Bio
KYNB
$28.2M
$96K 0.01%
95
-1
-1% -$929
ARNA
197
DELISTED
Arena Pharmaceuticals Inc
ARNA
$91K 0.01%
1,450
-20
-1% -$1.1K
INSM icon
198
Insmed
INSM
$29.4B
$86K ﹤0.01%
3,110
-40
-1% -$948
BHVN
199
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$83K ﹤0.01%
1,140
-10
-0.9% -$532
CDNA icon
200
CareDx
CDNA
$2.44B
$58K ﹤0.01%
1,650
-30
-2% -$854
6 7
8
9 10

Similar funds

M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
KFA
Krane Funds Advisors New York $2.44B AUM 12.99% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

Smith Group Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Smith Group Asset Management held 396 positions worth $1.81B, down 0.99% from $1.83B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Smith Group Asset Management withdrew a net $444M in Q2 2020, closing 98 positions and reducing 183 holdings. Its most notable exit was Biogen, an estimated $36M position sold in full.

By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 37% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Smith Group Asset Management opened a new position in Hologic worth $28M.

  • Smith Group Asset Management's largest Q2 2020 buy was Hologic: 490,762 shares worth $28M.
  • Smith Group Asset Management added most to Ameriprise Financial in Q2 2020, an estimated $15.8M increase.
  • Smith Group Asset Management's biggest Q2 2020 reduction was Apple, cutting an estimated $48.5M.
  • Smith Group Asset Management fully exited Biogen in Q2 2020, selling an estimated $36M.
  • Smith Group Asset Management's ten largest holdings make up 40% of its $1.81B portfolio in Q2 2020.
  • Smith Group Asset Management opened 38 new positions and closed 98 in Q2 2020.
  • Smith Group Asset Management's portfolio value fell 0.99% quarter-over-quarter to $1.81B.

Based on Smith Group Asset Management's 13F filing for Q2 2020, filed 6 Aug 2020.